SCHEMBL636057

SCHEMBL636057

CCOC(=O)C(N=C(c1ccccc1)c1ccccc1)c1ncc(C(F)(F)F)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.56
MEN1 O00255 3/20 0.56
MAPK1 P28482 1/20 0.53
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C19 P33261 1/20 0.52
RECQL P46063 1/20 0.52
HPGD P15428 2/20 0.48
GLA P06280 1/20 0.48
ALDH1A1 P00352 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 3/20 0.45
LMNA P02545 2/20 0.45
GAA P10253 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
HTT P42858 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18376119 0.79 AAK1 (0.39) KMT2AMEN1CYP1A2CYP3A4CYP2C19
SCHEMBL637918 0.78 KMT2A (0.67) KMT2AMEN1MAPK1CYP1A2CYP3A4
SCHEMBL5211782 0.78 KMT2A (0.82) KMT2AMEN1MAPK1CYP1A2CYP3A4
SCHEMBL29649689 0.78 KMT2A (0.82) KMT2AMEN1MAPK1CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL636048 0.77 KMT2A (0.66) KMT2AMEN1MAPK1CYP1A2CYP3A4
SCHEMBL2891610 0.77 KMT2A (0.77) KMT2AMEN1MAPK1CYP1A2CYP3A4
SCHEMBL4380392 0.76 KMT2A (0.67) KMT2AMEN1MAPK1CYP1A2CYP3A4
Ammonia Solution, Strong SCHEMBL6606007 0.76 KMT2A (0.67) KMT2AMEN1MAPK1CYP1A2CYP3A4
SCHEMBL5200890 0.75 GLA (0.47) KMT2AMEN1MAPK1HPGDGLA
SCHEMBL784479 0.74 ALDH1A1 (0.52) KMT2AMEN1MAPK1HPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565441-B1 Process for the preparation of 2-aminomethylpyridine derivatives BAYER CROPSCIENCE SA (FR) 2012-02-22 EP disclosed
US-7232911-B2 Process for the preparation of 2-aminomethylpyridine derivative BAYER CROPSCIENCE S.A. (FR) 2007-06-19 US disclosed
US-20060100441-A1 Process for the preparation of 2-aminomethylpyridine derivative BAYER CROPSCIENCE LIMITED (GB) 2006-05-11 US disclosed
EP-1565441-A2 PROCESS FOR THE PREPARATION OF 2-AMINOMETHYLPYRIDINE DERIVATIVE Bayer CropScience S.A. (FR) 2005-08-24 EP disclosed
WO-2004065359-A2 PROCESS FOR THE PREPARATION OF 2-AMINOMETHYLPYRIDINE DERIVATIVE BAYER CROPSCIENCE S.A. (FR) 2004-08-05 WO disclosed
EP-1422220-A1 Process for the preparation of 2-aminomethylpyridine derivative Bayer CropScience SA (FR) 2004-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100441-A1 Process for the preparation of 2-aminomethylpyridine derivative AZI2, CYP2C9, ABL2 KMT2A 302/4885MEN1 2143/4885MAPK1 974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.